Literature DB >> 26202292

Current histological classification of NAFLD: strength and limitations.

Pierre Bedossa1,2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of lesions ranging from pure steatosis without significant necroinflammatory injury (NAFL) to a complex pattern with lesions of hepatocyte injury and inflammation (nonalcoholic steatohepatitis, NASH) in the absence of significant alcohol intake. Because histopathological evaluation of liver biopsy samples remains central in NAFLD in the absence of a non-invasive test with enough accuracy, precise definition of each group is a key issue. When at least 5 % of hepatocytes display steatosis, patients can be qualified for NAFLD in an appropriate clinical context. When, in addition, lobular inflammation and liver cell clarification/ballooning are present, then the lesion can be qualified for NASH. Like for other chronic liver diseases, semiquantitative histological scoring has been proposed for NAFLD. These scoring systems are not useful in clinical practice, and each has some limitation. For comprehensive purposes, we suggest describing histopathological lesions in NAFLD using the SAF score, which assesses together and separately (1) the grade of steatosis (S, from S0 to S3) and (2) the grade of activity (A from A0 to A4 by adding the grades of ballooning and lobular inflammation, both from 0 to 2) and the stage of fibrosis (F from F0 to F4). Such a semiquantitative score could be used for assessing changes in paired biopsies spontaneously or during clinical trials. Finally, the SAF score could help to correctly describe borderline cases of fatty liver diseases that do not fulfill all of the diagnostic criteria of simple steatosis or steatohepatitis, but as for any scoring system, a comprehensive description of the different lesions in their appropriate context is still necessary.

Entities:  

Keywords:  Liver biopsy; NAFLD; NASH

Year:  2013        PMID: 26202292     DOI: 10.1007/s12072-013-9446-z

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  32 in total

1.  Sources of variability in histological scoring of chronic viral hepatitis.

Authors:  Marie-Christine Rousselet; Sophie Michalak; Florence Dupré; Anne Croué; Pierre Bedossa; Jean-Paul Saint-André; Paul Calès
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Epidemiology and natural history of non-alcoholic steatohepatitis.

Authors:  Curtis K Argo; Stephen H Caldwell
Journal:  Clin Liver Dis       Date:  2009-11       Impact factor: 6.126

4.  Triglyceride accumulation protects against fatty acid-induced lipotoxicity.

Authors:  Laura L Listenberger; Xianlin Han; Sarah E Lewis; Sylvaine Cases; Robert V Farese; Daniel S Ory; Jean E Schaffer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

5.  Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.

Authors:  Dawn M Torres; Frances J Jones; Janet C Shaw; Christopher D Williams; John A Ward; Stephen A Harrison
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

6.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

7.  Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

Authors:  Kanji Yamaguchi; Liu Yang; Shannon McCall; Jiawen Huang; Xing Xian Yu; Sanjay K Pandey; Sanjay Bhanot; Brett P Monia; Yin-Xiong Li; Anna Mae Diehl
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

8.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Aynur Unalp; Cynthia E Behling; Joel E Lavine; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory.

Authors:  Antônio Roberto Franchi Teixeira; Marta Bellodi-Privato; José Barreto Carvalheira; Victor Fernando Pilla; José Carlos Pareja; Luiz Augusto Carneiro D'Albuquerque
Journal:  Obes Surg       Date:  2009-12       Impact factor: 4.129

10.  Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease.

Authors:  Elizabeth M Brunt; Sunil Ramrakhiani; Barry G Cordes; Brent A Neuschwander-Tetri; Christine G Janney; Bruce R Bacon; Adrian M Di Bisceglie
Journal:  Mod Pathol       Date:  2003-01       Impact factor: 7.842

View more
  8 in total

Review 1.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

2.  Precise fibrosis staging with shear wave elastography in chronic hepatitis B depends on liver inflammation and steatosis.

Authors:  Junzhao Ye; Wei Wang; Shiting Feng; Yang Huang; Xianhua Liao; Ming Kuang; Xiaoyan Xie; Bing Liao; Bihui Zhong
Journal:  Hepatol Int       Date:  2020-02-20       Impact factor: 6.047

3.  Frequency of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus and its associated risk factors.

Authors:  Shaista Kanwal; Tahir Ghaffar; Azizul Hasan Aamir; Khalid Usman
Journal:  Pak J Med Sci       Date:  2021 Sep-Oct       Impact factor: 1.088

Review 4.  From the origin of NASH to the future of metabolic fatty liver disease.

Authors:  Andreas Geier; Dina Tiniakos; Helmut Denk; Michael Trauner
Journal:  Gut       Date:  2021-02-25       Impact factor: 23.059

5.  Tomato Juice Consumption Modifies the Urinary Peptide Profile in Sprague-Dawley Rats with Induced Hepatic Steatosis.

Authors:  Gala Martín-Pozuelo; Rocío González-Barrio; Gonzalo G Barberá; Amaya Albalat; Javier García-Alonso; William Mullen; Harald Mischak; María Jesús Periago
Journal:  Int J Mol Sci       Date:  2016-10-26       Impact factor: 5.923

6.  Correlation between severity of ultrasonographic nonalcoholic fatty liver disease and cardiometabolic risk among Filipino wellness patients.

Authors:  Lucky R Cuenza; Tamara Louise J Razon; Juan Carlo Dayrit
Journal:  J Cardiovasc Thorac Res       Date:  2017-06-08

7.  Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction.

Authors:  Junzhao Ye; Yanqin Wu; Fuxi Li; Tingfeng Wu; Congxiang Shao; Yansong Lin; Wei Wang; Shiting Feng; Bihui Zhong
Journal:  Therap Adv Gastroenterol       Date:  2019-09-26       Impact factor: 4.409

8.  Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease.

Authors:  Hannes Hagström; Olof Elfwén; Rolf Hultcrantz; Per Stål
Journal:  Gastroenterol Res Pract       Date:  2018-07-02       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.